Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Meaningful End Points for Patients with Metastatic Melanoma

May 10th 2023

Experts on skin cancer discuss valuable end points for determining successful treatments for patients with metastatic melanoma.

Deciding Between Melanoma Therapy Options

May 10th 2023

A panel of skin cancer experts share their thoughts on treatment selection for patients with melanoma.

IRAK-4 Inhibitor CA-4948 May Enhance Immunotherapeutic Outcomes in Melanoma With Brain Metastases

May 5th 2023

Bently Doonan, MD, discusses how CA-4948 can penetrate the blood-brain barrier and interact with the tumor microenvironment, and how this approach may open doors for patients with melanoma who have brain metastases.

Early ctDNA Testing Provides Another Tool for Predicting Survival Outcomes With Tebentafusp in Metastatic Uveal Melanoma

May 4th 2023

Ryan J. Sullivan, MD, discusses previous research on tebentafusp in uveal melanoma that led to the inception of the IMCgp100-202 trial and clinical implications for data confirming the predictive value of circulating tumor DNA levels.

Dr Sriramareddy on the Relationship Between Uveal Melanoma and the Liver Metastases

May 3rd 2023

Sathya Neelature Sriramareddy, MD, PhD, discusses how the interaction between uveal melanoma cells and the liver microenvironment could influence metastasis growth and therapeutic response.

Practical Advice on the Evolving Management of CSCC

May 3rd 2023

Closing out their discussion on the management of cutaneous squamous cell carcinoma, expert panelists share clinical pearls and excitement for the future.

BRAF/MEK Dual Inhibitors for Melanoma

May 3rd 2023

An expert panel analyzes BRAF/MEK dual inhibitor therapy for the treatment of melanoma.

Factors that Impact Treatment Selection for Melanoma

May 3rd 2023

Anna C. Pavlick, DO, discusses factors that impact treatment selection for patients with melanoma.

FDA Grants Regular Approval to Cemiplimab for Metastatic Basal Cell Carcinoma

May 1st 2023

The FDA has granted full approval to cemiplimab-rwlc for the treatment of patients with metastatic basal cell carcinoma who previously received a hedgehog inhibitor (HHI) or for whom a HHI is not appropriate.

A Phase 1 Clinical Trial Evaluating Monotherapy With Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF‑Altered Solid Tumors and NRAS-Mutant Melanoma

April 27th 2023

Alexander I. Spira, MD, PhD, shares new dose escalation data from the first-in-human Phase 1 KIN-2787 study of the pan-RAF inhibitor exarafenib in patients with BRAF-altered solid tumors or NRAS-mutant melanoma.

CSCC: Escalating Therapy for High-risk Patients

April 26th 2023

Dr Vishal Patel shares a surgeon’s perspective on MDC, followed by a discussion on how intensifying treatment after surgery may improve outcomes for higher-risk patients with CSCC.

Best Practices in Multidisciplinary Care for CSCC

April 26th 2023

Experts in the field of CSCC revisit the concept of multidisciplinary care and consider best communication strategies.

Future Treatment Landscape for Squamous Cell Carcinoma

April 26th 2023

Expert oncologists look to the future of treatment for cutaneous squamous cell carcinoma.

Treatment Duration Considerations for CSCC

April 26th 2023

Skin cancer expert Anna C. Pavlick, DO, discusses treatment duration approaches for cutaneous squamous cell carcinoma.

Darovasertib Plus Crizotinib Shows Early Promise in Metastatic Uveal Melanoma

April 24th 2023

The combination of darovasertib and crizotinib demonstrated clinical activity and an acceptable safety profile when utilized in first- and any-line patients with metastatic uveal melanoma.

Dr Sullivan on Pseudoprogression as a Potential Explanation for Outcomes With Tebentafusp in Uveal Melanoma

April 24th 2023

Ryan J. Sullivan, MD, explains the prolongation of survival with tebentafusp-tebn despite apparent initial radiographic tumor progression in patients with uveal melanoma.

Dr Sullivan on ctDNA Reduction After Tebentafusp Treatment in Uveal Melanoma

April 24th 2023

Ryan J. Sullivan, MD, discusses findings from a study investigating the effects of early circulating tumor DNA reduction on overall survival in patients with uveal melanoma treated with tebentafusp.

Dr Luke on Initial Data From the GLIMMER-01 Trial of E-602 in Advanced Solid Tumors

April 20th 2023

Jason J. Luke, MD, FACP, discusses initial results from the phase 1 GLIMMER-01 trial of E-602 in advanced solid tumors.

Other Emerging Treatment Modalities in Cutaneous Squamous Cell Carcinoma

April 19th 2023

Shared insight on novel treatment modalities in the setting of cutaneous squamous cell carcinoma and how they may be triaged moving forward.

CSCC: Translating Cemiplimab Data Into Practice

April 19th 2023

Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.